Table 3 Analyses regarding the prognostic factors for disease free survival.
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
CONUT | 1.486 (1.118–1.975) | 0.006 | 1.548 (1.127–2.125) | 0.07 |
CONUT ≤ 2 | ||||
CONUT ≥ 3 | ||||
Patient age | 0.673 (0.497–0.910) | 0.01 | 0.705 (0.507–0.980) | 0.037 |
≤40 | ||||
>40 | ||||
ER | 1.127 (0.812–1.564) | 0.475 | ||
+ | ||||
− | ||||
PR | 0.715 (0.536–0.954) | 0.022 | 0.737 (0.550–0.988) | 0.041 |
− | ||||
+ | ||||
HER2 | 0.874 (0.630–1.211) | 0.418 | ||
− | ||||
+ | ||||
Ki-67 status | 1.276 (0.930–1.749) | 0.131 | ||
− | ||||
+ | ||||
pT Stage | 1.404 (1.234–1.597) | <0.001 | 1.307 (1.123–1.522) | 0.001 |
1 | ||||
2 | ||||
3 | ||||
4 | ||||
pN Stage | 1.518 (1.307–1.764) | <0.001 | 1.333 (1.098–1.599) | 0.002 |
0 | ||||
1 | ||||
2 | ||||
3 | ||||
Molecular subtype | 0.983 (0.846–1.142) | 0.824 | ||
Luminal A | ||||
Luminal B | ||||
HER2-enriched | ||||
TNBC | ||||
Histological grade | 1.587 (1.723–2.15) | <0.001 | 1.476 (1.101–1.979) | 0.009 |
I-II | ||||
III | ||||
Surgery type | 1.112 (0.823–1.486) | 0.456 | ||
Mastectomy | ||||
BCS | ||||
Chemotherapy | 0.931 (0.756–1.268) | 0.631 | ||
No | ||||
Yes | ||||
Hormone therapy | 0.867 (0.754–1.625) | 0.374 | ||
No | ||||
Yes | ||||
Radiotherapy | 1.09 (0.826–1.468) | 0.561 | ||
No | ||||
Yes | ||||
Target therapy | 1.159 (0.876–1.542) | 0.32 | ||
No | ||||
Yes | ||||
